Table 2.

rs12959006 interaction with baseline‐measured anti‐HHV‐6, anti‐EBNA‐1, and anti‐EBNA‐2 IgG to predict CDMS and relapse among classic FDEs

Factor	Genotype	CDMS		p	Relapse		p
		N	HR (95% CI)		N	HR (95% CI)
Baseline HHV6	CC	23	0.63 (0.14, 2.77)	.54	27	0.58 (0.20, 1.64)	.30
	CT + TT	16	6.95 (1.11, 43.31)	.04	23	3.00 (1.19, 7.53)	.02
			p interaction	.05		p interaction	.02
Baseline EBNA1	CC	23	1.30 (0.57, 2.99)	.54	27	1.10 (0.57, 2.12)	.77
	CT + TT	16	3.01 (1.15, 7.87)	.02	23	1.28 (0.88, 1.87)	.19
			p interaction	.28		p interaction	.66
Baseline EBNA2	CC	23	1.12 (0.59, 2.14)	.73	27	1.13 (0.74, 1.73)	.57
	CT + TT	16	4.14 (1.62, 10.56)	.003	23	1.52 (0.90, 2.56)	.12
			p interaction	.19		p interaction	.68

HR, hazard ratio; CI, confidence interval; FDE, first demyelinating event.

Due to the smaller number people carrying TT genotype converted to CDMS (N = 2), we recoded the genotype as CT + TT. Results were adjusted for age, sex and study site, and presented as HR (95% CI) for CDMS and relapse. N refers to the number of events for each related clinical course. p value <0.05 bolded.